Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — FY2015 Earnings Presentation
22 slides from Neuland Laboratories's earnings presentation, May 2015
Slide 1: Investor Presentation | May 2015
COMPE> SS y RY IX NO CS x NEULAND NEULAND WHERE OPPORTUNITY BECOMES REALITY Investor Presentation | May 2015 BSE CODE : 524558 | NSE SYMBOL : NEULANDLAB | BLOOMBERG: NLL:IN | REUTERS: NEUL.NS © 2015 — Neuland Laboratories Limited. All Rights Reserved | www.neulandlabs.com A LCA Si
Slide 2: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and wow the subsequent discussions, which include words or phrases such as "will", "aim", "will likely mou nou wow mou result’, "would", "believe", "may", "expect", wou wou mou will continue", "antic
Slide 3: ik ds
Investor Presentation | Neuland Labs | www.neulandlabs.com ik ds 3 44 NEULAND
Slide 4: Company Overview
Company Overview 30+ 75+ 78 80+ 400+ 1500+ Years of Products Mn USD Countries of Regulatory Experienced excellence developed Revenue for FY business Filings professionals 15 including scientists * Headquartered in Hyderabad, India with two overseas office in USA and Japan * Two Business verticals :
Slide 5: The Journey
The Journey - Pt Diversified DPM mix 2014 Product Mix (DPM) 2011 High value niche Model strategy Shift launched Large 2004 portfolio of r APIs USA Operation r 1997 r 2007 First FDA 1994 : . Japan Operation 1986 Aud P P Strategic Manufacturing Neuland deal with Mitsubishi group goes public First API
Slide 6: Board and Key Management
Board and Key Management M.Sc. from Andhra University, Post Graduate Diploma in Technology - IIT Kharagpur Dr. DB R. Rao . Ph.D. in Organic Chemistry -University of Notre Dame, U.S.A. Chairman and Managing Has held senior positions in R & D, production and quality assurance at Glaxo India Director &
Slide 7: Board and Key Management
Board and Key Management Dr. Christopher M. Ph.D. in Organic Chemistry - Purdue University, U.S.A. Cimarusti Post Doctoral Research - Columbia University, U.S.A. Non-executive Director Former Sr. Vice President, Pharmaceutical Development - Bristol-Myers Squibb Professor of International Management,
Slide 8: • • • • • • • • • • • • • •
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
Slide 9: Business Mix
Business Mix + API Heritage of 30 years * 2USFDA and EU GMP compliant manufacturing facilities * Collective capacity with 525 KL * Flexible 100g to hundreds ton capacity * World wide customer base 80+ countries * Project management systems underpin CRM * EHS Record + 75 APIs across 10 diverse areas
Slide 10: Regulatory Filings and IPR
Regulatory Filings and IPR Regulatory Agency No. of DMFs registered USFDA 48 Canada 23 EU 378 EDQM (COS) 19 Japan 5 Korea 9 Others (ROW) 84 Investor Presentation | Neuland Labs | www-neulandlabs.com K de 10 A: NEULAND
Slide 11: Industry structure and key drivers
Industry structure and key drivers API Industry's Share in Global Contract Manufacturing Industry Key Drivers ¢ Increased demand for biopharmaceutical manufacturing services Finished * Complex and potent drug development will Dosage ‘ormulations 33% lead to higher demand of High Potency Active Forec
Slide 12: ik ds
Investor Presentation | Neuland Labs | www.neulandlabs.com ik ds 12 44 NEULAND
Slide 13: 1.2 0.9 0.9 0.8 0.8 2011 2012 2013 2014 2015 2.8 2.5 1.9 1.5
1.2 0.9 0.9 0.8 0.8 2011 2012 2013 2014 2015 2.8 2.5 1.9 1.5 1.2 2011 2012 2013 2014 2015 2.7 2.8 2.8 2.5 2.1 2011 2012 2013 2014 2015
Slide 14: Highlights- FY15
Highlights- FY15 Q4 Update va) > i “ 2 = 2 < 2 a5 Successfully scaled up four new products in the antipsychotic and anticoagulant segment Received first set of revenues from Japanese deal with APIC USPTO granted a patent for improved process synthesis of Paliperidone Palmitate Received the 2015 CMO
Slide 15: ik N
Investor Presentation | Neuland Labs | www.neulandlabs.com ik N 15 44 NEULAND
Slide 16: Business Strategy
Business Strategy Exports higher volumes to Japan and other regulated markets Add new therapies and products having high margins Add more capacity and consolidate existing with a profitable product basket File DMFs, Patents and grow intangibly. Create an organization that results in value for all st
Slide 17: Higher margins with complex molecules APIs
Higher margins with complex molecules APIs Faster Growth with high volume APIs Bring sustainability fo e A . Investor Presentation | Neuland Labs | www.neulandlabs.com Me NEULAND
Slide 18: Actual FY15 vs Projected for FY18
100% 100% Actual FY15 Projected for FY 18 90% 90% 80% 80% 70% 70% 20 products > 20% MS 12 products > 40% MS 60% 60% 17 products > INR 20 Cr Total No. Of Products: 43 50% 50% 40% 40% 30% 30% 20% 20% 0 10 20 30 40 50 60 70 0 20 40 60 80 100 10% 10% 0% 0%
Slide 19: Growth in CMS
Growth in CMS ° 11 development labs ° = 2kilo labs ° 2manufacturing sites e 55 fume hoods e cGMP pilot plant with two ° 11 diverse production blocks * mg togm scale production areas ° — Kg to ton scale ° Analytical R&D ° — 0.5-50 kg batch size Scale the revenue growth in CMS from 15% to 30% Investor
Slide 20: Investment Rationale
Investment Rationale Horizontal Growth = Continued expansion as preferred API source world wide = Enhance manufacturing capacity to sustain high growth in APIs and CMS = Increased number of new products with focus on market share on existing products through process improvement and capacity utilizat
Slide 21: For further information contact:
For further information contact: Bhamidipati Sarada Ankit Gupta Company Secretary Christensen A / +91 40 3021 1685 +91 22 42150210 [email protected] [email protected] NEULAND WHERE OPPORTUNITY BECOMES REALITY
Slide 22: Key FII holders
Shareholding Pattern as on 31%t March, 2015 Others, 45.7% Promoters, 51.7% Key Fil holders FIl:ICGQ Dils, 1.0% Fils, 1.5% Investor Presentation | Neuland Labs | www.neulandlabs.com K he NEULAND